Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Denosumab
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $2,800.0 million Upfront Cash: $2,800.0 million
Deal Type: Collaboration January 02, 2020
Details:
The stratagic collaboration between Amgen and BeiGene will significantly accelerate Amgen's plans to expand its oncology presence in China.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
